IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1201-1225 out of 1245.

<< < 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>

Public Release: 26-Jun-2014
Genome Medicine
New test predicts the risk of non-hereditary breast cancer
A simple blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, even in the absence of a high-risk BRCA1 gene mutation, according to research published in the open access journal Genome Medicine.
The Eve Appeal, National Institute for Health Research

Contact: Shane Canning
University College London

Public Release: 26-Jun-2014
Cancer Epidemiology, Biomarkers & Prevention
Continued use of low-dose aspirin may lower pancreatic cancer risk
The longer a person took low-dose aspirin, the lower his or her risk for developing pancreatic cancer, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
NIH/National Cancer Institute

Contact: Jeremy Moore
American Association for Cancer Research

Public Release: 26-Jun-2014
Scientists find potential new use for cancer drug in gene therapy for blood disorders
Scientists working to make gene therapy a reality have solved a major hurdle: bypassing a blood stem cell's natural defenses and insert disease-fighting genes into the cell's genome. In a study led by Associate Professor Bruce Torbett at The Scripps Research Institute, researchers report the drug rapamycin, commonly used to slow cancer growth and prevent organ rejection, enables delivery of a therapeutic dose of genes to blood stem cells while preserving stem cell function.
National Insitutes of Health, Canadian CIHR Doctoral Research Award, California HIV/AIDS Research Program, Center/AIDS Research

Contact: Mika Ono
Scripps Research Institute

Public Release: 26-Jun-2014
Cancer Cell
Diabolical duo: Known breast cancer gene needs a partner to initiate and spread tumors
A team led by Princeton University researchers has found that a gene known as Metadherin promotes the survival of tumor-initiating cells via the interaction with a second molecule called SND1. The finding could suggest new treatment strategies.
US Department of Defense, National Institutes of Health, Cancer Institute of New Jersey

Contact: Catherine Zandonella
Princeton University

Public Release: 26-Jun-2014
Journal of Interferon & Cytokine Research
Which interferons best control viral infections?
Respiratory and intestinal infections caused by RNA viruses stimulate infected cells to produce interferons, which can act alone or in combination to block virus replication. Important differences between the presence of IFN receptors on cells and new evidence that specific types of IFNs can control RNA virus infection are explored in a Review article in Journal of Interferon & Cytokine Research.

Contact: Kathryn Ruehle
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 26-Jun-2014
General Hospital Psychiatry
Researchers conduct comprehensive review of treatments for depression in cancer patients
When depression co-exists with cancer, patients may be at an increased risk of death from cancer and from suicide. Antidepressants are commonly prescribed, but the evidence on their efficacy is mixed. The role of antidepressants in treating cancer-related depression has not been rigorously studied. To identify best practice for the treatment of depression in cancer, Dartmouth researchers completed a systematic review and meta-analysis of existing research.

Contact: Robin Dutcher
The Geisel School of Medicine at Dartmouth

Public Release: 26-Jun-2014
Clinical Cancer Research
Researchers home in on way to predict aggressiveness of oral cancer
Studying mouth cancer in mice, researchers have found a way to predict the aggressiveness of similar tumors in people, an early step toward a diagnostic test that could guide treatment, according to researchers at Washington University School of Medicine in St. Louis.
National Institutes of Health

Contact: Julia Evangelou Strait
Washington University School of Medicine

Public Release: 26-Jun-2014
New infections cause dormant viruses to reactivate
The famous slogan is 'A diamond is forever,' but that phrase might be better suited to herpes: Unlike most viruses, which succumb to the immune system's attack, herpes remains in the body forever, lying in wait, sometimes reactivating years later.
National Institutes of Health

Contact: April Frawley
University of Florida

Public Release: 25-Jun-2014
SIAM Journal on Mathematical Analysis
Using math to analyze movement of cells, organisms, and disease
A few recent SIAM journal papers that use math to analyze movement of organisms and cells and transmission of disease in populations.

Contact: Karthika Muthukumaraswamy
Society for Industrial and Applied Mathematics

Public Release: 25-Jun-2014
First positive results toward a therapeutic vaccine against brain cancer
A prerequisite to the development of a tumor vaccine is to find protein structures in cancer cells that differ from those of healthy cells. Cancer researchers from Heidelberg have now been able to develop a mutation-specific vaccine targeting a protein that is mutated in brain cancer. In the journal 'Nature,' the researchers report that the vaccine arrested tumor growth in mice.

Contact: Dr. Sibylle Kohlstädt
German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)

Public Release: 25-Jun-2014
ESMO World Congress on Gastrointestinal Cancer 2014
Annals of Oncology
MM-398 added to standard treatment shows survival benefit in mets pancreatic cancer
Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Contact: ESMO Press Office
European Society for Medical Oncology

Public Release: 25-Jun-2014
International Journal of Radiation Oncology • Biology • Physics
Special edition of the Red Journal highlights the need for radiation oncology services in LMICs
The July 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics, the official scientific journal of the American Society for Radiation Oncology, features a special section of 10 articles focusing on global health and radiation oncology in low- and middle-income countries.

Contact: Brittany Ashcroft
American Society for Radiation Oncology

Public Release: 25-Jun-2014
MicroRNA that blocks bone destruction could offer new therapeutic target for osteoporosis
UT Southwestern cancer researchers have identified a promising molecule that blocks bone destruction and, therefore, could provide a potential therapeutic target for osteoporosis and bone metastases of cancer.

Contact: Russell Rian
UT Southwestern Medical Center

Public Release: 24-Jun-2014
Nature Communications
Cancer: The roots of evil go deep in time
Every year around 450,000 people in Germany are diagnosed with cancer. Each one of them dreams of a victory in the battle against it. But can cancer ever be completely defeated? Researchers at Kiel University have now reached a sobering conclusion.

Contact: Claudia Eulitz
Kiel University

Public Release: 24-Jun-2014
Proceedings of the National Academy of Sciences
Cell division discovery could optimise timing of chemotherapy and explain some cancers
Research led by the University of Warwick in collaboration with groups in Nice and Rotterdam has been able to demonstrate how the cycle of cell division in mammalian cells synchronizes with the body's own daily rhythm, its circadian clock. The study not only helps to explain why people with sustained disrupted circadian rhythms can be more susceptible to cancer, it may also help establish the optimal time of day to administer chemotherapy.
Biotechnology and Biological Sciences Research Council

University of Warwick

Public Release: 24-Jun-2014
Cancer Research
Mayo Clinic researchers say gene in brain linked to kidney cancer
A gene known to control brain growth and development is heavily involved in promoting clear cell renal cell carcinoma, the most common form of kidney cancer, researchers from Mayo Clinic in Florida are reporting.
NIH/National Cancer Institute

Contact: Kevin Punsky
Mayo Clinic

Public Release: 24-Jun-2014
To advance care for patients with brain metastases: Reject five myths
Professional pessimism and out-of-date 'myths,' rather than current science, are guiding and compromising the care of patients with cancer that has spread to the brain, says a blue-ribbon panel of experts from leading academic centers in an article published online June 24 in Neurosurgery. The authors identify five key misconceptions that must be addressed -- and how to address them -- in order to advance new thinking in the treatment of brain cancer.

Contact: Ryan Jaslow
NYU Langone Medical Center / New York University School of Medicine

Public Release: 24-Jun-2014
Cancer Biology & Therapy
Virus kills triple negative breast cancer cells, tumor cells in mice
A virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice, according to Penn State College of Medicine researchers. Understanding how the virus kills cancer may lead to new treatments for breast cancer.
Pennsylvania Breast Cancer Coalition

Contact: Matt Solovey
Penn State

Public Release: 24-Jun-2014
Journal of Experimental Medicine
New possibilities for leukemia therapy with a novel mode of leukemia cell recognition
Scientists at A*STAR's Singapore Immunology Network have discovered a new class of lipids in the leukemia cells that are detected by a unique group of immune cells. By recognizing the lipids, the immune cells stimulate an immune response to destroy the leukemia cells and suppress their growth. The newly identified mode of cancer cell recognition by the immune system opens up new possibilities for leukemia immunotherapy.

Contact: Tan Yun Yun
Biomedical Sciences Institutes (BMSI)

Public Release: 24-Jun-2014
Experts cite 'misconceptions' on brain metastases
'Key historical misconceptions' are hindering progress in research and treatment for patients with cancer metastases to the brain, suggests a special article in the July issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

Contact: Connie Hughes
Wolters Kluwer Health

Public Release: 24-Jun-2014
Master regulator of key cancer gene found, offers new drug target
A key cancer-causing gene, responsible for up to 20 percent of cancers, may have a weak spot in its armor, according to new research from the Masonic Cancer Center, University of Minnesota. The partnership of MYC, a gene long linked to cancer, and a non-coding RNA, PVT1, could be the key to understanding how MYC fuels cancer cells. The research is published in the latest issue of the journal Nature.
Masonic Cancer Center University of Minnesota, Sarcoma Fund, American Cancer Society

Contact: Caroline Marin
University of Minnesota Academic Health Center

Public Release: 24-Jun-2014
Nature Scientific Reports
UT Arlington nanoparticles could provide easier route for cell therapy
UT Arlington physics researchers may have developed a way to use laser technology to deliver drug and gene therapy at the cellular level without damaging surrounding tissue. The method eventually could help patients suffering from genetic conditions, cancers and neurological diseases.
National Science Foundation, National Institutes of Health

Contact: Traci Peterson
University of Texas at Arlington

Public Release: 24-Jun-2014
Journal of Clinical Investigation
Synthetic triterpenoids show promise in preventing colitis-associated colon cancer
Researchers from Case Western Reserve and Dartmouth universities have shown that a class of small antioxidant molecules carries enormous promise for suppressing colon cancer associated with colitis. These findings, published in an early June edition of the Journal of Clinical Investigation, offer hope that physicians ultimately will be able to reduce dramatically the number of sufferers of this inflammatory bowel disease who go on to develop colon cancer.
National Institutes of Health

Contact: Jeannette Spalding
Case Western Reserve University

Public Release: 24-Jun-2014
New transdermal SARM drug for muscle-wasting offers hope for older cancer patients
Muscle wasting that occurs as a result of cancer negatively impacts the well-being and recovery prospects of millions of patients, particularly the rapidly-growing elderly populations in Western societies. Drugs called selective androgen receptor modulators (SARMs) offer hope for these patients, and a new SARM for transdermal administration is promising excellent efficacy without harming liver function and HDL levels. Results and conclusions were presented Tuesday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

Contact: Aaron Lohr
The Endocrine Society

Public Release: 24-Jun-2014
Nature Reviews Cancer
CNIO researcher Ana Losada revises the role of cohesin in cancer
Ana Losada, the head of the Chromosome Dynamics Group at the Spanish National Cancer Research Centre, an international expert in cohesin, summaries in Nature Reviews Cancer the latest research on the role of cohesin, its regulation, as well as its recently identified function as a potential driver or facilitator for tumors.

Contact: Nuria Noriega
Centro Nacional de Investigaciones Oncologicas (CNIO)

Showing releases 1201-1225 out of 1245.

<< < 44 | 45 | 46 | 47 | 48 | 49 | 50 > >>